{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:36:25Z","timestamp":1791308185921,"version":"4.3.1"},"reference-count":94,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1053\/j.seminoncol.2016.02.010","type":"journal-article","created":{"date-parts":[[2016,2,8]],"date-time":"2016-02-08T18:01:37Z","timestamp":1454954497000},"page":"280-290","source":"Crossref","is-referenced-by-count":25,"title":["Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia"],"prefix":"10.1053","volume":"43","author":[{"given":"Tadeusz","family":"Robak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerzy Z.","family":"Blonski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Robak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2016.02.010_bib1","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1586\/17474086.2014.963048","article-title":"Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art","volume":"7","author":"Robak","year":"2014","journal-title":"Expert Rev Hematol"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1053\/j.seminhematol.2014.05.005","article-title":"Incorporating targeted agents into future therapy of chronic lymphocytic leukemia","volume":"51","author":"Pallasch","year":"2014","journal-title":"Semin Hematol"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib3","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1200\/JCO.2014.55.8262","article-title":"Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician","volume":"32","author":"Byrd","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/11539590-000000000-00000","article-title":"New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies","volume":"25","author":"Robak","year":"2011","journal-title":"BioDrugs"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib5","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1200\/JCO.2003.09.027","article-title":"Single-agent rituximab as firstline and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network","volume":"21","author":"Hainsworth","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib6","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1200\/JCO.2001.19.8.2153","article-title":"Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity","volume":"19","author":"Byrd","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib7","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1200\/JCO.2001.19.8.2165","article-title":"Rituximab dose-escalation trial in chronic lymphocytic leukemia","volume":"19","author":"O\u2019Brien","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib8","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1182\/blood.V98.5.1326","article-title":"Rituximab therapy of patients with B-cell chronic lymphocytic leukemia","volume":"98","author":"Huhn","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1034\/j.1600-0609.2002.02786.x","article-title":"Standard dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study","volume":"69","author":"Itala","year":"2002","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib10","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1002\/cncr.25853","article-title":"Experience with rituximab immunotherapy as an early intervention in patients with Rai stage 0 to II chronic lymphocytic leukemia","volume":"117","author":"Ferrajoli","year":"2011","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib11","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/cncr.23144","article-title":"Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia","volume":"112","author":"Del Poeta","year":"2008","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib12","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1185\/03007995.2011.615307","article-title":"Single-agent rituximab in treatment-refractory or poor prognosis patients with chronic lymphocytic leukemia","volume":"27","author":"Wiernik","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib13","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1182\/blood-2013-05-502773","article-title":"Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia","volume":"122","author":"Abrisqueta","year":"2013","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib14","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.2217\/fon.13.219","article-title":"Ofatumumab: a novel, fully human anti-CD20 monoclonal antibody for the treatment of chronic lymphocytic leukemia","volume":"9","author":"Barth","year":"2013","journal-title":"Future Oncol"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib15","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood-2007-09-111781","article-title":"Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study","volume":"111","author":"Coiffier","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib16","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1200\/JCO.2009.25.3187","article-title":"Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia","volume":"28","author":"Wierda","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib17","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib18","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1586\/17474086.2014.953478","article-title":"Obinutuzumab for chronic lymphocytic leukemia","volume":"7","author":"Rioufol","year":"2014","journal-title":"Expert Rev Hematol"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib19","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/blood-2014-07-586610","article-title":"Obinutuzumab (GA101) in relapsed\/refractory chronic lymphocytic leukemia: final data from the phase 1\/2 GAUGUIN study","volume":"124","author":"Cartron","year":"2014","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib20","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib21","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40265-013-0167-3","article-title":"Obinutuzumab: first global approval","volume":"74","author":"Cameron","year":"2014","journal-title":"Drugs"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib22","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1158\/1078-0432.CCR-11-0850","article-title":"Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in Fc\u03b3RIIIa-genotyped patients with previously treated follicular lymphoma","volume":"18","author":"Forero-Torres","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib23","doi-asserted-by":"crossref","first-page":"749","DOI":"10.4161\/mabs.28282","article-title":"Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia","volume":"6","author":"Cheney","year":"2014","journal-title":"MAbs"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib24","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3109\/10428194.2014.911859","article-title":"Phase 1\/2 Study of Ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low affinity Fc\u03b3RIIIa patients with previously treated follicular lymphoma","volume":"56","author":"Ganjoo","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib25","doi-asserted-by":"crossref","first-page":"747","DOI":"10.3109\/10428191003672123","article-title":"Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects","volume":"51","author":"Goldenberg","year":"2010","journal-title":"Leuk Lymph"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib26","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2008-07-168146","article-title":"Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody","volume":"113","author":"Goldenberg","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib27","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1200\/JCO.2008.19.9117","article-title":"Humanized anti-CD20 antibody, veltuzumab, in refractory\/recurrent non-Hodgkin\u2019s lymphoma:phase I\/II results","volume":"27","author":"Morschhauser","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib28","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3324\/haematol.2010.037390","article-title":"Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin\u2019s lymphoma","volume":"96","author":"Negrea","year":"2011","journal-title":"Haematologica"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib29","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.192.192","article-title":"Monotherapy with subcutaneous (SC) injections of low doses of humanized anti-CD20 veltuzumab is active in chronic lymphocytic leukemia (CLL). ASH Annual Meeting Abstracts","volume":"120","author":"Kalaycio","year":"2012","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib30","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1056\/NEJM200208083470619","article-title":"Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy","volume":"347","author":"Stilgenbauer","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib31","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood-2003-10-3729","article-title":"Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions","volume":"103","author":"Lozanski","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib32","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","article-title":"Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study","volume":"99","author":"Keating","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib33","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1182\/blood-2009-05-224071","article-title":"Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL):dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial","volume":"114","author":"Zenz","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib34","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1200\/JCO.2007.12.9098","article-title":"Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia","volume":"25","author":"Hillmen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib35","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1200\/JCO.1997.15.4.1567","article-title":"Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European study group of CAMPATH-1H treatment in chronic lymphocytic leukemia","volume":"15","author":"Osterborg","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib36","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1365-2141.2011.08965.x","article-title":"An Italian retrospective study on the routine clinical use of low-dose alemtuzumab in relapsed\/refractory chronic lymphocytic leukaemia patients","volume":"156","author":"Cortelezzi","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib37","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1200\/JCO.2008.21.1128","article-title":"Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group","volume":"27","author":"Stilgenbauer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib38","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3109\/10428199509059636","article-title":"CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy","volume":"18","author":"Scheuermann","year":"1995","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib39","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1182\/blood-2009-06-229039","article-title":"CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody","volume":"115","author":"Awan","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib40","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1182\/blood-2014-08-593269","article-title":"A phase I trial of the Fc engineered CD19 antibody XmAb\u00ae5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed chronic lymphocytic leukemia","volume":"124","author":"Woyach","year":"2014","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib41","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1365-2141.2011.08857.x","article-title":"A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo","volume":"155","author":"Ward","year":"2011","journal-title":"Br J Haematol."},{"issue":"suppl","key":"10.1053\/j.seminoncol.2016.02.010_bib42","article-title":"MEDI-551, an anti-CD19 antibody active in chronic lymphocytic leukemia (CLL) patients previously treated with rituximab","volume":"31","author":"Hamadani","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib43","doi-asserted-by":"crossref","first-page":"6448","DOI":"10.1158\/1078-0432.CCR-11-0485","article-title":"SAR3419: An Anti-CD19-maytansinoid immunoconjugate for the treatment of B-cell malignancies","volume":"17","author":"Blanc","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib44","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1158\/1078-0432.CCR-13-0580","article-title":"A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"20","author":"Ribrag","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib45","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1182\/blood-2007-03-082024","article-title":"Mediation of apoptosis by and anti-tumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines","volume":"111","author":"Pathan","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib46","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1158\/1078-0432.CCR-06-1463","article-title":"Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia","volume":"13","author":"Byrd","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib47","first-page":"489","volume":"115","author":"Byrd","year":"2010","journal-title":"Phase 1\/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib48","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/bjh.13061","volume":"167","author":"Awan","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib49","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1517\/14712598.2014.890182","article-title":"Anti-CD37 antibodies for chronic lymphocytic leukemia","volume":"14","author":"Robak","year":"2014","journal-title":"Expert Opin Biol Ther"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib50","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/bjh.13099","article-title":"Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR(\u2122) therapeutic protein, for relapsed or refractory NHL patients","volume":"168","author":"Pagel","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib51","first-page":"1383","article-title":"TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies","volume":"10","author":"Robak","year":"2009","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib52","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2006-12-062927","article-title":"Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical","volume":"110","author":"Zhao","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib53","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1016\/j.ejca.2014.07.021","article-title":"Pro-apoptotic effect of an anti-CD37 scFv-Fc fusion protein, in combination with the anti-CD20 antibody, ofatumumab, on tumour cells from B-cell malignancies","volume":"50","author":"Smolewski","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib54","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.135.135","article-title":"NK Cells Contribute Significantly to the Innate Immune Effector Role of CD37-Specific SMIP in CLL and NHL. ASH Annual Meeting Abstracts","volume":"108","author":"Zhao","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib55","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1182\/blood-2013-07-512137","article-title":"A phase 1 study evaluating the safety and tolerability of otlertuzumab (TRU-016), an anti-CD37 mono-specific ADAPTIRTM therapeutic protein in chronic lymphocytic leukemia","volume":"123","author":"Byrd","year":"2014","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib56","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.2860.2860","article-title":"Phase 2 study of otlertuzumab (TRU-016), an anti-CD37 ADAPTIRTM protein, in combination with bendamustine vs bendamustine alone in patients with relapsed chronic lymphocytic leukemia (CLL). ASH Annual Meeting Abstracts","volume":"122","author":"Robak","year":"2013","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib57","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.1182\/blood-2011-04-351932","article-title":"A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies","volume":"118","author":"Heider","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib58","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1182\/blood-2013-05-505685","article-title":"A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies","volume":"122","author":"Deckert","year":"2013","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib59","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1038\/leu.2014.32","article-title":"The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model","volume":"28","author":"Beckwith","year":"2014","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib60","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/978-0-387-89520-8_2","article-title":"Therapeutic interventions targeting CD40L (CD154) and CD40: the opportunities and challenges","volume":"647","author":"Law","year":"2009","journal-title":"Adv Exp Med Biol"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib61","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1182\/blood-2007-04-084756","article-title":"The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells","volume":"112","author":"Luqman","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib62","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.3109\/10428194.2012.681655","article-title":"Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia","volume":"53","author":"Byrd","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib63","doi-asserted-by":"crossref","first-page":"8331","DOI":"10.1158\/0008-5472.CAN-05-0095","article-title":"Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40","volume":"65","author":"Law","year":"2005","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib64","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.1583.1583","article-title":"Preclinical analysis of the combined activity of SGN-40, anti-CD40 monoclonal antibody, with rituximab in Non-Hodgkin lymphoma. ASH Annual Meeting Abstracts","volume":"112","author":"Lewis","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib65","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1365-2141.2008.07548.x","article-title":"The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by. lenalidomide in chronic lymphocytic leukaemia","volume":"144","author":"Lapalombella","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib66","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3109\/10428190903440946","article-title":"A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia","volume":"51","author":"Furman","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib67","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/cyto.b.20567","article-title":"Variables affecting the quantitation of CD22 in neoplastic B cells","volume":"80","author":"Jasper","year":"2011","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib68","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s40259-013-0016-7","article-title":"Targeting CD22 in B-cell malignancies: current status and clinical outlook","volume":"27","author":"Sullivan-Chang","year":"2013","journal-title":"BioDrugs"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib69","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1182\/blood-2008-08-173195","article-title":"A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity","volume":"113","author":"Weldon","year":"2009","journal-title":"Blood"},{"issue":"18 Pt 2","key":"10.1053\/j.seminoncol.2016.02.010_bib70","doi-asserted-by":"crossref","first-page":"5556s","DOI":"10.1158\/1078-0432.CCR-07-1167","article-title":"CD74: a new candidate target for the immunotherapy of B-cell neoplasms","volume":"13","author":"Stein","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib71","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1517\/13543780903463854","article-title":"Milatuzumab\u2014a promising new immunotherapeutic agent","volume":"19","author":"Berkova","year":"2010","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib72","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1182\/blood-2009-11-253203","article-title":"Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells","volume":"116","author":"Hertlein","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib73","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/onc.2013.31","article-title":"CD84 is a survival receptor for CLL cells","volume":"33","author":"Binsky-Ehrenreich","year":"2014","journal-title":"Oncogene"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib74","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3109\/08830185.2013.786711","article-title":"BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies","volume":"32","author":"Robak","year":"2013","journal-title":"Int Rev Immunol"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib75","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib76","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(14)70335-3","article-title":"Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study","volume":"15","author":"Burger","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib77","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.525.525","article-title":"Ibrutinib in combination with bendamustine and rituximab is active and tolerable in patients with relapsed\/refractory CLL\/SLL: final results of a phase 1b study. ASH Annual Meeting Abstracts","volume":"122","author":"Brown","year":"2013","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib78","doi-asserted-by":"crossref","unstructured":"Chanan-Khan A, Cramer P, Demirkan F, et al. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26655421 Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016;17: 200\u201311","DOI":"10.1016\/S1470-2045(15)00465-9"},{"issue":"Suppl 15","key":"10.1053\/j.seminoncol.2016.02.010_bib79","article-title":"A phase Ib\/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) and related diseases. ASCO Annual Meeting Abstracts","volume":"30","author":"Jaglowski","year":"2012","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.1053\/j.seminoncol.2016.02.010_bib80","article-title":"Use of tumor genomic profiling to reveal mechanisms of resistance to the BTK inhibitor ibrutinib in chronic lymphocytic leukemia (CLL). 2013 ASCO Annual Meeting Abstracts","volume":"31","author":"Chang","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib81","article-title":"Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors","author":"Cheng","year":"2014","journal-title":"Leukemia"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib82","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood-2013-11-535047","article-title":"Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110\u03b4, for relapsed\/refractory chronic lymphocytic leukemia","volume":"123","author":"Brown","year":"2014","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib83","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"issue":"suppl","key":"10.1053\/j.seminoncol.2016.02.010_bib84","article-title":"A phase III, randomized, controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL)","volume":"31","author":"Flinn","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib85","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2011-03-339077","article-title":"Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia","volume":"118","author":"Badoux","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib86","doi-asserted-by":"crossref","first-page":"5343","DOI":"10.1200\/JCO.2005.05.0401","article-title":"Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study","volume":"24","author":"Chanan-Khan","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib87","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1200\/JCO.2010.29.8133","article-title":"Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia","volume":"29","author":"Chen","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib88","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-07-4405","article-title":"Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells","volume":"14","author":"Wu","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib89","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1200\/JCO.2012.42.8623","article-title":"Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia","volume":"31","author":"Badoux","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib90","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1200\/JCO.2013.51.5890","article-title":"Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the Chronic Lymphocytic Leukemia Research Consortium","volume":"32","author":"James","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib91","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.720.720","article-title":"Combination of ofatumumab and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL): results of a phase II trial. ASH Annual Meeting Abstracts","volume":"120","author":"Ferrajoli","year":"2012","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib92","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3109\/10428194.2014.935369","article-title":"Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma","volume":"56","author":"Costa","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib93","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/bjh.12457","article-title":"ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets","volume":"163","author":"Vogler","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminoncol.2016.02.010_bib94","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775416000166?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775416000166?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T03:47:57Z","timestamp":1600141677000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775416000166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":94,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0093775416000166"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2016.02.010","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]}}}